Infectious Disease Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 ID deals median ~$30M upfront, ~$400M total. Long-acting injectable HIV and RSV programs are exceptions with 2–3x multiples. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Infectious Disease deal benchmarks at a glance
Median deal terms for infectious disease licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $30M | $400M | 3–7% |
| Phase 1 | $80M | $700M | 5–10% |
| Phase 2 | $200M | $1.4B | 7–14% |
| Phase 3 | $450M | $2.5B | 10–20% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- Pfizer–GBT (sickle cell, $5.4B)
- GSK–Tesaro
- ViiV (Pfizer/Shionogi/GSK long-acting HIV)
Why Infectious Disease is priced this way
Post-COVID, infectious disease dealmaking has consolidated around antivirals (long-acting HIV, RSV, broad-spectrum) and anti-microbial resistance. Lower multiples than chronic conditions.
Try it live
Run a Infectious Disease deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Infectious Disease licensing — frequently asked
What is the median upfront payment for a Infectious Disease licensing deal?
How are Infectious Disease deal milestones structured?
What royalty rates are typical for Infectious Disease licensing?
Is there a free Infectious Disease deal calculator?
How does Infectious Disease licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited infectious disease deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime